M Vigier

574 total citations
12 papers, 326 citations indexed

About

M Vigier is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, M Vigier has authored 12 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 6 papers in Hematology. Recurrent topics in M Vigier's work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (4 papers). M Vigier is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (4 papers). M Vigier collaborates with scholars based in France and United States. M Vigier's co-authors include Philippe Moreau, Nöel Milpied, Jean‐Luc Harousseau, Beatrice Mahé, Nadine Morineau, Berthe‐Marie Imbert, Hervé Richet, Odile Morin, Laurence Legros and Marie‐Paule Mellerin and has published in prestigious journals such as Blood, Cancer and Clinical Infectious Diseases.

In The Last Decade

M Vigier

12 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M Vigier France	9	150	147	120	96	59	12	326
Vincenzo Mettivier Italy	10	115 0.8×	57 0.4×	85 0.7×	60 0.6×	58 1.0×	13	262
Ian H Gabriel United Kingdom	7	146 1.0×	85 0.6×	52 0.4×	98 1.0×	102 1.7×	14	399
Geothy Chakupurakal Germany	12	156 1.0×	126 0.9×	60 0.5×	53 0.6×	31 0.5×	28	369
Léonardo Magro France	11	270 1.8×	119 0.8×	116 1.0×	30 0.3×	38 0.6×	43	469
J.G. Fuzibet France	9	155 1.0×	65 0.4×	61 0.5×	35 0.4×	50 0.8×	37	341
Péter Reményi Hungary	13	228 1.5×	89 0.6×	135 1.1×	18 0.2×	54 0.9×	44	400
Takayuki Tabayashi Japan	12	108 0.7×	100 0.7×	72 0.6×	46 0.5×	74 1.3×	43	365
Ilaria Giardini Italy	11	265 1.8×	43 0.3×	137 1.1×	41 0.4×	40 0.7×	22	365
Chiara Frairia Italy	10	147 1.0×	100 0.7×	90 0.8×	59 0.6×	37 0.6×	24	296
Kaichi Nishiwaki Japan	12	476 3.2×	111 0.8×	227 1.9×	35 0.4×	31 0.5×	48	587

Countries citing papers authored by M Vigier

Since Specialization

Citations

This map shows the geographic impact of M Vigier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Vigier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Vigier more than expected).

Fields of papers citing papers by M Vigier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Vigier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Vigier. The network helps show where M Vigier may publish in the future.

Co-authorship network of co-authors of M Vigier

This figure shows the co-authorship network connecting the top 25 collaborators of M Vigier. A scholar is included among the top collaborators of M Vigier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Vigier. M Vigier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Houot, Roch, Steven Le Gouill, Christiane Mounier, et al.. (2011). Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Annals of Oncology. 23(6). 1555–1561. 36 indexed citations

2.

Gressin, Rémy, Steven Le Gouill, Mario Ojeda‐Uribe, et al.. (2008). Interim Results of the RiPAD+C Regimen Including Velcade in Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group.. Blood. 112(11). 1575–1575. 7 indexed citations

3.

Réa, Delphine, Laurence Legros, Emmanuel Raffoux, et al.. (2006). High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 20(3). 400–403. 46 indexed citations

4.

Guilhot, François, Martine Gardembas, Philippe Rousselot, et al.. (2003). Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials. Seminars in Hematology. 40(2 Suppl 2). 92–97. 9 indexed citations

5.

Mahé, Beatrice, Nöel Milpied, Marie‐Paule Mellerin, et al.. (2003). PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma. Bone Marrow Transplantation. 31(6). 467–473. 11 indexed citations

6.

Gardembas, Martine, Philippe Rousselot, Michel Tulliez, et al.. (2003). Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood. 102(13). 4298–4305. 44 indexed citations

7.

Guilhot, François, Martine Gardembas, Philippe Rousselot, et al.. (2003). Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials. Seminars in Hematology. 40(2). 92–97. 1 indexed citations

8.

Oudard, Stéphane, Martine Escoffre‐Barbe, B Desablens, et al.. (2002). Treatment of patients with advanced or bulky Hodgkin disease with a 12‐week doxorubicin, bleomycin, vinblastine, and dacarbazine‐like chemotherapy regimen followed by extended‐field, full‐dose radiotherapy. Cancer. 95(10). 2169–2179. 8 indexed citations

9.

Vigouroux, S., Nöel Milpied, J.M. Andrieu, et al.. (2002). Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. Bone Marrow Transplantation. 29(10). 833–842. 10 indexed citations

10.

Moreau, Philippe, Nöel Milpied, Nadine Morineau, et al.. (2002). Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma. Leukemia. 16(9). 1838–1843. 13 indexed citations

11.

Milpied, Nöel, Philippe Moreau, Nadine Morineau, et al.. (2001). Longitudinal Study of Bacterial, Viral, and Fungal Infections in Adult Recipients of Bone Marrow Transplants. Clinical Infectious Diseases. 33(1). 41–47. 103 indexed citations

12.

Avet‐Loiseau, Hervé, M Vigier, Philippe Moreau, et al.. (1997). Comparative genomic hybridization detects genomic abnormalities in 80% of follicular lymphomas. British Journal of Haematology. 97(1). 119–122. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact